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1. Introduction
1.1. The acute phase response (APR) and haptoglobin (Hp)
Acute phase response is a stereotyped innate nonspecific reaction of the body proceeding
specific immune reactions. It´s a systemic homeostatic reaction of the organism to local and or
systemic disturbances caused by infections, tissue injury, trauma, immunologic disorders and
neoplasias (Ron D et al 1990, Trautwein C et al 1994, Gruys E et al 2005). Proinflammatory
cytokines are released at the place of tissue injury, diffuses locally and systemically to the
vascular system and activates receptors on different target cells resulting in the activation of
hypothalamic-pituitary-adrenal axis (HPAA), results in the production of growth hormone
secretion and induces changes in the concentration of several plasma proteins (Ron D et al 1990,
Trautwein C et al 1994, Gruys E et al 2005).
These acute phase proteins (APPs) can be positive (higher levels in plasma) or negative (lower
levels in plasma). The alteration on mRNA in hepatocytes is due to simultaneous influence of
systemic cytokines (IL1, IL6 and TNFα), glucocorticoids and catecholamines (Bowman BH
1993, Ron D et al 1990, Trautwein C et al 1994).
Haptoglobin together with fibrinogen, α-globulins with antiprotease-activity and lipopoly‐
saccharide binding protein belong to the group of positive APPs that increase 3-fold in
mammals (Trautwein C et al 1994, Gruys E et al 2005).
Haptoglobin (Hp) is an acute phase α2 plasma glycoprotein that is a component of innate
immunity, which also may influence acquired immunity. Through both types of immunity,
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Hp is involved in the pathogenesis of tumours and infections (Langlois MR and Delanghe JR
1996, Van Vlierberghe H. et al 2004, Levy AP et al 2010).
2. Haptoglobin (Hp) synthesis, gene structure, variants and its geographic
distribution
Haptoglobin locus is on chromosome 16q22 and its gene is transcribed and translated into a
single peptide which undergoes post-translational processing resulting in a smaller α-chain
and a longer β-chain linked by disulphide bridge (Giblett ER 1968, Langlois MR and Delanghe
JR 1996, Wicher KB and Fries E 2007).
In 1955, Smithies, using thin layer starch gel electrophoresis identified the three phenotypes
of Hp (1-1, 2-1, 2-2), corresponding to the α-chain length interindividual genetic variation.
The three genotypes are shown in electrophoresis in polyacrylamide gel electrophoresis
(PAGE) (fig 1).
This genetic variation results from an internal duplication of a gene segment (exons 3 and 4),
correspondent to α-chain of Hp1 giving rise to a larger one, characteristic of Hp2 (Maeda et
al 1984, Wicher KB and Fries E 2007).
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Figure 1. Typical pattern of haptoglobin bands in a polyacrylamide gel electrophoresis (PAGE). Shown are the pheno‐
types: Hp 1-1, is characterized by a fast migration band; Hp 2-2 is characterized by slower multiple bands; Hp 2-1,
characterized by a mixed pattern of two allelic forms. The ultrafast bands are no haptoglobin bound haemoglobin
chains (Linke RP 1984, Guerra J et al 1997).
This inter-individual variation is found only in humans and aroused about 100,000 years ago
in Southeast Asia. The great majority of other mammals have only one band corresponding to
the human Hp1-1, except the sheep, deer and cows (Ruminantia), which have only slow bands
corresponding to Hp2-2 (Bowman BH and Kurosky A 1982, Wicher KB and Fries 2007).
The appearance of Hp2 can represent an important evolutionary genetic contribution for
interpopulational diversity in human pathology (ER Giblett 1968, Maeda et al 1984, Wicher
KB and Fries 2007). This allele is predominant in the human population (about 80% in some
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ethnic groups) and Hp1 allele is more predominant in populations subjected to malaria burden
(Giblett ER 1968, Langlois MR and Delanghe JR 1996, Wobeto VP et al 2008, Levy AP et al
2010).
In close linkage with haptoglobin gene there is another one, 2-2 Kb downstream from Hp locus,
coding for Hp related (Hpr) plasma protein with 91% sequence identity to Hp1. The α-chain
of Hpr contains a hydrophobic signal peptide that may explain its association to lipoprotein
particles (HDL) or membranes (Kuhajda FP et al 1989 a, b).
3. Haptoglobin locals of its synthesis and regulation
The Hp gene is expressed primarily in hepatocytes and more recently has been described in
other locations, such as keratinocytes, airway epithelial cells of lung, leucocytes, fibrocytes,
adipocytes and endometrial cells, particularly during the blastocyst implantation (Friederichs
WE et al 1995, Olson EG et al 1997 Wang et al 2005, Shaw JL et al 2007, Yang F 2000 et al, Larsen
K et al 2006, and Theilgaard-Mönch K et al 2006).
Haptoglobin synthesis is induced by cytokines such as interleukin-6 (IL-6), interleukin-1 (IL-1)
and tumour necrosis factor (TNFα) released by the macrophages, after activation of the innate
immunity cells by PAMPs (pathogen associated molecular patterns) such as lipopolysacchar‐
ide, a TLR4 (Toll Like Receptor) activator (Raynes JG et al 1991, Kaisho T and Alkira S 2002).
Glucocorticoids and catecholamines activate haptoglobin synthesis previously induced by
interleukins (increased), whereas insulin exerts an opposite action, despite the presence of
these interleukins (Ron D et al 1990, Campos SP and Baumann H 1992 Nascimento CO et al
2004, Gruys E et al 2005 and XiaLi-xin et al 2008). Hypoxia also induces indirectly its synthesis
(Wenger RH et al 1995, Oh Mi-Kyung et al 2011).
4. Haptoglobin metabolism, actions and respective mechanisms
Haptoglobin has a pronounced anti-inflammatory action, which is explained by its ability to
bind to heme of haemoglobin, forming a Hp-Hb complex. This is characterized by stability
and high affinity to its specific type scavenger receptor (CD163) located in the hepatocyte and
the phagocytic-type cells such as circulating monocytes, resident macrophages (M2) and liver
Kupffer cells. The CD163 is a membrane protein 130-kDa, whose long extracellular region has
nine cysteine-rich domains of scavenger-type receptor (Graversen JH et al 2002, Nielsen MJ et
al 2010, Akila P et al 2012). The expression of receptors (CD 163), Hp and hemoxygenase (HO-1),
is strongly activated by antinflammatory cytokines, such as interleukins (IL6, IL10), growth
factors (M-CSF) and glucocorticoids (Moestrup SK and Møller H 2004). In contrast CD 163 is
down regulated by IL4 and GM-CSF, Interferon γ and TNF (Nielsen MJ et al 2010, Vallelian F
et al 2011 and Akila P et al 2012).
After binding to its receptor the Hp-Hb complex is internalized in the form of endosome,
followed by fusion with lysosomes, proteolysis of globin and intracellular release of heme to
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hemoxygenase (HO-1) with concomitant formation of biliverdin that is converted in bilirrubin,
CO (carbon monoxide) and release of iron to ferritin where is compartmentalised (Graversen
JH et al 2002, Nielsen MJ et al 2010, Vallelian F et al 2011, Akila P et al 2012).
The small protein Hp1-1 is excreted in the urine when occurs kidney damage, however, the
Hp2-1 and Hp2-2 are always retained (Fagoonee S 2005). The clearance of free haemoglobin
(Hb) after intravascular haemolysis by the haptoglobin is higher in individuals carrying the
Hp1 allele (Giblett ER 1968, Langlois MR and Delanghe JR 1996, Moestrup SK and Møller H
2004, Nielsen MJ et al 2010, Vallelian F et al 2011, Akila P et al 2012).
The free Hb has the ability to catalyse the formation of hydroxyl radicals (OH·), from the
hydrogen peroxide, with highly damaging effects to the cellular constituents and extracellular
macromolecules (Sadrzadeh SMH 1984, Gutteridge JMC 1987).
The Hp-Hb complex, reduces the loss of Hb in urine and concomitant loss of iron and its
transport is done mainly to the liver. As a result, the removal of free Hb has much important
consequences for the organisms, preventing renal injury that may occur when the free Hb
passes through the glomerular filter (Fagoonee S et al 2005). Also Hp prevents the promotion
of free radicals and its accumulation in endothelial cells, catalysed by heme, where it causes
vessel injury (Nielsen MJ et al 2010, Vallelian F et al 2011 and Akila P et al 2012). However, there
is a great variability in these responses, which is dependent of Hp polymorphism having
individuals with the Hp2-2 a lower antioxidant capacity than those with other phenotypes.
Furthermore at the extra-vascular interstitial level, the antioxidant capacity of carriers of Hp2-2
is lower, because of its higher molecular mass that restricts its extravascular diffusion (Langlois
MR and Delanghe JR 1996, Van Vierberghe et al 2004, Fagoonee S. et al 2005, Levy AP et al 2010).
Levels of haptoglobin in plasma or serum are lower in healthy infants than adults whose
concentrations are between 0.38 and 2.08g/l (Langlois MR and Delanghe JR 1996). These steady
state levels are consequence of haptoglobin half-life of 3.5 days and Hp-Hb complex of ten
minutes (Sadrzadeh SMH and Bozorgmehr J 2004). The Hp can also be detected in urine and
other organic fluids (Langlois MR and Delanghe JR 1996, Sadrzadeh SMH and Bozorgmehr J
2004). The half-life of Hp-Hb complex is phenotype dependent being Hp1-1 shorter than Hp2-2
(Levy AP et al 2010). Plasma concentrations are also phenotype dependent, people with Hp1-1
having the highest, Hp2-1 intermediate and Hp2-2 lesser concentrations in plasma (Langlois
MR and Delanghe JR 1996).
Haptoglobin levels are quantified by chemical and immunochemical methods, from these the
most utilised are the immunonephelometric and immunoturbidimetric methods that are
automated (Langlois MR and Delanghe JR 1996, Sadrzadeh SMH and Bozorgmehr J 2004).
The haptoglobin polymorphism is most commonly determined by starch or polyacrylamide
electrophoresis (Fig 1). When plasma levels are lower than 0.10g/l PCR based assays are utilised
(Linke RP 1984, Langlois MR and Delanghe JR 1996, Guerra A et at 1997, Levy AP et al 2010).
More recently in both, levels measurement and phenotype, are utilised new proteomic
methods based on two dimensional gel electrophoresis and quantitative determination by
mass spectrometry (MALDI-TOF-MS and SELDI-TOF-MS) methods (Gast M-C et al 2008, Chen
C-B et al 2008).
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The Hp-Hb complex also binds nitric oxide or nitrogen monoxide (NO), produced by cytokine
activated macrophages, thus preventing their physiological and pathological actions (Langlois
MR and Delanghe JR 1996, Azarov I et al 2008, Alayash A 2011). Also this action is phenotype
dependent, because Hp2-2/Hb complex scavenge more NO than Hp1-1/Hb due to its longer
half-life (Azarov I et al 2008, Levy AP et al 2010, Alayash A 2011).
The Hp is also a potent endogenous inhibitor of prostaglandin synthesis, resulting in anti-
inflammatory action. The inhibitory effects of Hp2-2 and Hp2-1 are less pronounced than those
of Hp1-1 (Kendall PA et al 1979, Langlois MR and Delanghe JR 1996, Saeed SA et al 2007).
Haptoglobin has also bacteriostatic effects, because the capture and compartmentalization of
the iron of Hb made it no longer available for bacterial growth. The Hp 2-2 is more efficient
than the other phenotypes in this action against Streptococcus. There are also microorganisms
that can remove iron from the Hp-Hb complex (Langlois MR and Delanghe JR 1996, Weinberg
ED 1996, Van Vlierberghe et al 2004).
The role of Hp in angiogenesis has been identified as one of the factors for modulation of
differentiation and proliferation of endothelial cells during the formation of new vessels (Cid
MC et al 1993, Park SJ 2009). Free Hb can promote indirectly carcinogenesis through the iron
that is necessary for cell growth. The withholding of iron inhibits cell growth and depresses
the immune system (Langlois MR and Delanghe JR 1996, Weinberg ED 1996).
The local increased concentration of Hp in chronic inflammatory processes is important for
the ischemic tissue reparation, promoting collateral vessel formation. Of the three genetic
forms Hp2.2 is the most angiogenic (Cid MC et al 1993).
In resident tissues macrophages (M2 type), carbon monoxide (CO) resulting from the intra‐
cellular degradation Hp-Hb complex appears to be involved in anti-inflammatory effects of
interleukin 10 (IL-10). The suppression of these immune and inflammatory responses results
from its ability to decrease the antigen presentation and cytokine synthesis. This mechanism
of regulation is more active in patients with the Hp1-1 phenotype that has a greater clearance
of their complexes with their CD163 receptors present on monocytes, than for those carrying
the phenotype Hp2-2 (Nielsen MJ et al 2010, Vallelian F et al 2011 and Akila P et al 2012).
In macrophages, after the endocytosis of the Hp-Hb complex and CD163, increased levels of
cytoplasmic iron ocurr, inducing the synthesis of ferritin, a primary iron storage, which can
subtract it from inflammation site (Cozzi et al 2004). The activation of the CD 163 also induces
a signal mediated by protein tyrosine kinase, leading to the secretion of anti-inflammatory
cytokines and giving rise to a connection between the clearance function of the Hp and their
immunomodulatory functions (Van Vlierberghe et al 2004, Guetta et al 2007, Nielsen MJ et al
2010, Vallelian F et al 2011 and Akila P et al 2012).
Haptoglobin can also modulate the immune response by binding to receptors on immune cells,
such as CD22 on B lymphocytes and β2 integrin (CD11b/CD18) in neutrophils or LFA-1
(lymphocyte function associated antigen-1) in T lymphocytes (EL Ghmati SM et al 1996,
Giannoni E et al 2003, Bottini N et al 2005). The Hp may bind to neutrophils, inhibiting NADPH
oxidase activation and the production of reactive forms of oxygen associated with inflamma‐
tion (Moestrup SK and Møller H, 2004, Guetta et al 2007).
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Changes of the ratio of lymphocytes Th1 and Th2 are important for the determination of
susceptibility to viral and parasitic infections, for allergies, for antitumor responses and
autoimmunity (Gleeson ME 2006, Clerici M et al 1998). It was shown that Hp plays a modu‐
lating role of the Th1/Th2 ratio, promoting a Th2 dominant response, which is more pro‐
nounced in patients with the Hp1-1 and 2-1 phenotypes (Bottini N et al 2005, Guetta et al 2007).
The objective of this chapter is to review the scientific evidence of haptoglobin role, as an
immune innate protein in the several aspects of cancer biology and its possible clinical
importance as a genetic and a circulating biomarker for that pathology.
The methodology for this review is based in the search in the literature of relevant studies in
cancer concerning both the circulating levels of haptoglobin (including the recent described
fucosylated glicans), haptoglobin related (Hpr) and the genetic variation studies, in the
Medline Data Bases and the related papers, since the first reports in the sixties of the last century
until actuality. A special attention will be a consideration of cancer associated with human
papillomavirus (HPV). The keywords used in the search will be haptoglobin, cancer genetics,
circulating levels and clinics.
5. Haptoglobin (Hp) and its related pathway as biomarkers in cancer
Genetic polymorphism of haptoglobin leads to its functional differences resulting in interin‐
dividual variation of the related intermediate phenotypes at the different biological levels that
can constitute circulating biological markers of clinical importance not only for the suscepti‐
bility but also for the prognostic and response to treatment at the diverse levels of natural
history of the neoplasia disease (Bicho MC 2011). We will review by organs and systems the
studies that evidence those aspects.
In table 1, we describe the association of Hp polymorphism in several populations with CNS
head and neck, lung, blood and skin malignancies.
For the central nervous system it was demonstrated that haptoglobin is transcribed and
expressed (proteomic methods) in human glioblastome cells and it is significantly associated
with greater plasmatic levels in the higher grades compared with lower ones and those of
control subjects (Sanchez DJ et al 2001, Kumar DM et al 2010). Also it was demonstrated that
Hp increases in vitro glioblastome cell migration (Kumar DM et al 2010), table 1.
Head and neck squamous cell cancer (HNSCC) is a term that collectively refers to cancer of
oral cavity, salivary glands, larynx and pharynx. After a first study the authors whose objective
is discovery of circulating biomarkers associated with those tumours, demonstrate in HNSCC
in general and nasopharynx in particular, the haptoglobin overexpression, in a stage and
tumour volume dependency (Chen C-B et al 2008, Lee CC et al 2009). Another group confirmed
the involvement of the Hp phenotype in infection with Epstein-Barr virus (EBV) that is
associated with nasopharynx carcinoma (Speeckaert R et al 2009).
In the eighties several studies of association with cancer of acute phase proteins in particular
haptoglobin were done, that is the case for the lung cancer in 309 Swedish patients where the
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Hp1 allele is more frequent in women with adenocarcinoma (Beckman G et al 1986). More
recently other group confirmed the association of local higher levels of the Hp l expression in
pulmonary adenocarcinomas in opposition to squamous cell carcinomas (SCC) and small cell
carcinomas (Abdullah M 2009).
There are five references for blood malignancies such as acute and chronic lymphoid leukemia
and acute myeloid leukemia from three different ethnic groups Sweden, Israel and Brazil
(Caucasians and Afro-descendants) and only one sample of Ashkenazy Jews (Germinis A et
al 1983, Nevo S and Tatarsky I 1986, Mitchell RJ et al 1988, Fröhlander N and Stendahl U 1988,
Campregher PV et al 2004).
Cutaneous malignancies and in particular squamous cell carcinoma (SCC)/Bowen´s disease
are more frequent in kidney transplanted patients, that are more prone to disease when are
Neoplasia Population (N)(Control/Neo) Conclusions References
Human glioblastome N=26/96India Hp2 allele higher grades
Sanchez DJ et al 2001;
Kumar DM et al 2010
Head/neck squamous
cell cancer N=135/163 Hp2 allele tumour volume dependency Chen C-B et al 2008
N=134/49
Taiwan Lee CC et al 2009
Nasopharynx
carcinoma
N=918/208
Belgium
Hp1-1 and Hp 2-1 less prone to positive EBV
serology Speeckaert R et al 2009
Lung cancer N=309 Sweden Hp1 allele more frequent in adenocarcinoma infemales Beckman G et al 1986
Acute lymphoid
leukemia
N=2331/110
Sweden No association
Fröhlander N and Stendahl
U 1988
Leukemias N= 211Israel Associated Hp1-1 with ALL, AML, CML Nevo S and Tatarsky I 1986
Acute myeloid
leukemia
N=197/188
Brazil Campregher PV et al 2004
ALL, AML, CML, IgA ML N=134 Australia Higher Hp 1-1 association Mitchell RJ et al 1988Germinis A et al 1983
Squamous cell
carcinoma (SCC) N=300 Belgium
Hp phenotype 1.1 more prone to develop SCC
in kidney transplanted patients Speeckaert R et al 2012
Kaposi´s sarcoma Hp1.1 phenotype more prone Speeckaert R et al 2011
Abbreviations: ALL-Acute lymphatic leukaemia; AML- Acute myeloid leukaemia; CML- Chronic myeloid leukaemia; CLL-
Chronic lymphatic leukaemia; ML- Myeloma.
Table 1. Haptoglobin and Cancer: Various Tumours.
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carriers of Hp 1.1 phenotypes particularly after ten years of the transplantation (Speeckaert R
et al 2012). The same happens in the development of Kaposi´s sarcoma in HIV positive patients,
even after adjustment for age, gender and AIDS status (Speeckaert R et al 2011).
Tumours of gastrointestinal tract where also studied and the single reference to haptoglobin
polymorphism in colon cancer refers to one association in 184 Greek patients of Hp1-1
phenotype (Archimandritis A et al 1993), table 2.
More recently it was shown that Hp is produced in a large molecular complex with the beta
chain of urokinase in cancer cells as well as in capillary endothelial cells (Harvey S et al 2009).
This cancer-associated glycoform of Hp (β-chain) is a ligand for Galectin-3, a beta-galactoside
binding protein implicated in tumour progression and metastases of colorectal cancers
(Bresalier RS et al 2004).
Neoplasia Population (N)(Control/Neo) Conclusions References
Colon cancer N=2026/184Greece Association of Hp1-1 phenotype Archimandritis A et al 1993
Gastric cancer N=104/100India Risk for Hp2-2 carriers Jayanthi M et al 1989
N=114/2026
Greece No association Theodoropoulos G et al 1992
Oesophageal cancer Higher risk for Hp2-1 phenotype Jayanthi M et al 1989
Pancreatic cancer N=11/11China Frequency of Hp 2-2 is higher Deng R et al 2007
Table 2. Haptoglobin and Cancer: Digestive Tumours.
Geographic differences have been reported regarding the influence of the Hp alleles in cancer
risk. In India, where the frequency of Hp2 allele is high at the population level (84%) the risk
for gastric cancer of the Hp2-2 phenotype carriers is 4.04 and the risk for oesophageal is 3.86
for Hp2-1 phenotype carriers (Jayanthi M et al 1989). On the contrary in another geographic
localization (Greece) a study of a similar number of gastric carcinoma patients didn’t show
any difference for the same polymorphism (Theodoropoulos G et al 1992).
Deng R et al demonstrated in 2007 that, in pancreatic carcinoma patients, the frequency of Hp
2-2 is higher compared with chronic pancreatitis patients and normal controls. Haptoglobin
of these patients is not elevated in serum, but it is abnormally fucosylated in β-chain that has
four N-glycans sites, the same happens but not so extensively in hepatocellular, gastric and
colorectal carcinomas. The fucosylation of Hp seems to be induced by a factor secreted by these
tumours itself (Nakano et al 2009, Miyoshi E, Nakano M 2008)
Early references of the distribution of haptoglobin polymorphism in Greek patients with
prostate carcinoma compared with prostate benign hypertrophy (BPH) patients failed to
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demonstrate any association (Germenis A et al 1983, Dimopoulos MA et al 1984). These results
were consistent with a recent report from an association study realized in an African popula‐
tion where the Authors didn´t also demonstrate any association of the Hp polymorphism with
PSA (Prostate Specific Antigen) and prostate cancer patients survival (Mavondo GA et al 2012).
However there were demonstrated higher circulation levels of monoclonal antibodies against
glycosyl epitopes presents in the beta chain of Hp in prostate carcinoma compared with BPH
that decreased after radical prostatectomy (Saito S et al 2008), table 3.
Serum levels of haptoglobin were elevated in kidney and bladder cancer concomitantly with
a metabolite of Prostaglandin F2α, however only in bladder cancer was demonstrated in 264
Germans a statistically significant lower frequency of Hp2-2 genotype (Dunzendorfer U et al
1981; Bemkman HG et al 1987).
Neoplasia Population (N)(Control/Neo) Conclusions References
Prostate cancer N=155/115
Greek patients
Failed to demonstrate any Hp
association
Germenis A et al 1983; Dimopoulos MA
et al 1984
N=122/74
Africa, Botswana
Zimbabwe
Any association of the
polymorphism with PSA and
survival
Mavondo GA et al 2012
Bladder cancer N=264
Germany
Lower frequency of Hp 2-2 Benkman HG et al 1987
Table 3. Haptoglobin and Cancer: Urological Tumours.
For breast cancer despite consistency of overrepresentation of Hp 1 allele in three earlier
studies (Tsamantains C et al 1980, Kaur H et al 1984, Bartel U et al 1985) and only one negative
study (Hudson BL et al 1982) a more recent study demonstrate that Hp phenotype distribution
in patients is family history-dependent. For these authors the frequency of Hp 1-1 and Hp 2-1
phenotypes is higher in the familial group and the opposite for the no familial group (Awa‐
dallah S and Atoum MF 2004). Moreover, in the recent study whose objective was to search
for circulating proteins, predictive of recurrences and free survival of high risk primary breast
cancer, with proteomic techniques (SELDI-TOF-MS) the authors, based on disturbances of iron
(low levels of ferritin light chain is associated with good prognosis), identified Hp 2 allele as
risk factor, nonetheless validated in an independent, sample and technique group of patients
(Gast M-C W et al 2008). Also, it may have clinical important value, as a biomarker for
recurrence in early breast cancer patients, the haptoglobin related (Hpr) protein in tissues and
plasma (Kuhajda FP et al 1989 a-b).
The first references from the sixties of the last century about gynaecologic tumours indicate
contradictory results between the authors when they were analyzed as a whole in what
concerns to the frequency of Hp1 allele (Larkin MF 1967, Milunicova A et al 1969). However,
a posterior reference of Bartel U et al 1985 confirms a higher Hp1-1 genotype frequency in 246
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German patients with gynaecological and breast tumours. When only ovarian cancer samples
were considered, two references, one Polish and another Swedish, indicate they are associated
respectively with Hp 1 allele and Hp2-1 phenotype in patients with family history (Dobrys‐
zycka W and Wavas M. 1983, Fröhlander N and Stendahl U 1988).
Cervical neoplasia is a good model that illustrates haptoglobin and its polymorphism influence
in the several steps of its natural history interacting with oncogenic and non-oncogenic HPV
(Human Papillomavirus) and other co-factors such as sexual steroid hormones and smoking
habits (Bicho MC 2011).
Preliminary reports on the role of this haptoglobin polymorphism in the development of
cervical cancer were conflicting, with two authors (Milunicova and Bartel) indicating that Hp1
allele carriers were at risk of cancer development. In opposition, Larkin et al report the Hp2
allele as the most represented in their cervical cancer cases (Milunicova A et al 1969, Bartel U
et al 1985 U, Larkin M 1967). Those reports were published previous to the, nowadays
confirmed, association of oncogenic HPV types as the primary etiologic factor of cervical cancer
and the HPV effect was not evaluated in the control populations. However, HPV is a necessary
but not a sufficient cause of cervical cancer and it is also important the presence the other co-
factors host related. One of these co-factors can be the immune response of the host. It has been
proposed a role for haptoglobin a one of such co-factors (Mahmud SM et al 2007, Bicho MC et
al 2006 and 2009).
In the case control study conducted in Canada (307 cases vs 358 control women), Mahmud et
al examined the association of Hp phenotype with high grade cervical intraepithelial neoplasia
(CIN III), a precursor lesion of invasive carcinoma (ICC). The control group had to present a
normal cytology and HPV genotyping was performed to evaluate the HPV oncogenic type
status. Accordingly, only when the risk analysis is restricted to the HPV positive women, an
association was observed and Hp 1-1 carriers have almost a threefold increased susceptibility
to the development of CIN III (OR=2.7, 95% IC: 1.0-7.2) (Mahmud SM et al 2007). In a recent
study, we report an increased susceptibility for women that are Hp 1-1 carriers to develop ICC
(OR=4.62, 95% IC: 1.86-11.48) (Bicho MC 2011). These results are consistent with another study
performed in a different geographic localization (Ghana) and indicating a significant protec‐
tive effect for the Hp2 allele in homozygous women (Quaye IK et al 2009). In another report,
we studied the influence of Hp polymorphism on the risk for the development of HSIL and
ICC (n=196) under the influence of sex steroid hormones. We found that the risk for an
interaction is proportionally higher with the number of Hp 1 allele presents (Bicho MC et al
2009). However, when the interaction between Hp polymorphism with smoking habits was
studied the Hp 2 allele in homozygoty increased the risk to develop HSIL and ICC (Bicho MC
et al 2006).
6. Discussion
During the first thirty years (from the sixties to nineties of the last century) of cancer association
studies, genetic blood markers, including haptoglobin were concomitantly studied with
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descriptive studies of allele distribution in the different populations (Giblett ER 1968, Langlois
MR and Delanghe JR 1996, Wobeto VP et al 2008, Levy AP et al 2010). These preliminary reports
usually were cross-sectional case control studies, that didn’t enter in consideration with the
biological plausibility in cancer linked to the genetic variation. Diverse geographic regions,
with very different distribution of alleles, various genetic variations backgrounds and above
Neoplasia Population (N)(Control/Neo) Conclusions References
Breast cancer N=109Greece
Overrepresentation of Hp 1
allele Tsamantains C et al 1980
N=50/50
India
Overrepresentation of Hp 1
allele Kaur H et al 1984
N=246
Germany
Overrepresentation of Hp 1
allele Bartel U et al 1985
N=129/200
Jordania Higher frequency of Hp 1 allele Awadallah S
Familial (N=42)
Non familial (N=86)
Higher frequency of Hp 1 and
Hp 2 alleles Atoum MF 2004
USA No association Hudson BL et al 1982
N=371
USA No association Gast M-C W et al 2008
Ovarian cancer N=114/132Polland Associated Hp 1 allele
Dobryszycka W and Wavas M.
1983
N=182
Swedish
Associated Hp2-1 phenotype
with family history Fröhlander N and Stendahl U 1988
Cervical cancer N=170/85Checoslovakia Hp1 allele carriers at risk Milunicova A et al 1969
N=430/526
Germany Hp1 allele carriers at risk Bartel U et al 1985
N=430/526
USA
Hp2 allele as the most
represented Larkin M 1967
N=358/307 Canada In HPV positive women, risk forHp 1-1 is higher CIN III Mahmud SM et al 2007
N= 396/196
Portugal
In ICC women the risk for Hp
1-1 carriers is greater in steroid
hormone ingestion
Bicho MC 2011
N=120/60
Ghana
Protective effect of the Hp2
allele in homozygoty Quaye IK et al 2009
Table 4. Haptoglobin and Cancer: Gynaecological Tumours.
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all have different environments that interacts with genomes to give highly variable pheno‐
types, may explain controversial results.
Moreover, the lack of reproducibility of the several studies may also reflect methodological
differences in the criteria of case definitions and selection of controls, and in what concerns to
the influence of environment of factors such as microbiological (HPV, EBV, M. tuberculosis,
H. Pylori, Plasmodia), smoking habits, sun exposition, xenobiotic and sex steroid hormones
(Beckman G et al 1986, Benkmann HG et al 1987, Bicho MC et al 2006 and 2009, Mahmud et al
and 2007, Abdullah M et al 2009, Speeckaert R et al 2011 and 2012).
The usual cross-sectional approach of these studies didn´t take into account the somewhat
different influences of the genotypes on the natural story of the cancer that courses in multistep
way (Zur Hausen H 2002). The great majority of the studies were done in patients with distant
phenotypes (advanced stage cancer) and take not in consideration the subclinical disease. This
isn´t evidenced in those times by lack of knowledge of physiopathology and lack of reliable
biomarkers (circulating and imaging) that gives a more dynamic picture of the situation.
It was not common, the realization of measurements of serum and plasma levels of the Hp
independently of phenotype in part due too time consuming of the technics (Langlois MR and
Delanghe JR 1996). In these cases, not even the local processes are reflected in circulation but
also it is demonstrated the existence of a local tissue environment in what Hp functions in
paracrine and autocrine way (Yang F et al 2000, Xie Y, et al 2000, Sharpe-Timms et al 2002, Wang
H et al 2005, Shaw JLV et al 2007).
The natural history of cervical cancer seems to be dependent of genetic polymorphism of
haptoglobin in its interaction with HPV and cofactors such as sex steroid hormones and
smoking habits (Bicho MC et al 2006 and 2009, Mahmud et al and 2007).
Also there are reports of the different influences of Hp alleles in a context of familiar history
for the breast and ovarian cancers (Fröhlander N and Stendahl U 1988, Awadallah S and Atoum
MF 2004).
For the clarification of these issues a better knowledge of the physiopathology mechanisms of
action of the Hp alleles is necessary.
Haptoglobin as a pleiotropic protein has several different functions being the Hp1 allele and
correspondent genotypes Hp1-1 and Hp1-2, the more represented in the several cancers
reviewed. The innate immune response of the host against the tumour is limited in the subject’s
carriers of the Hp1 allele through several mechanisms, already reviewed.
It is accepted, in this pathway, the role of Hp-Hb, CD163, HO-1, CO, bilirubin, activation of
anti-oxidant intracellular systems (including ferritin), and extrusion of iron through ferropor‐
tin. This pathway is characteristic of immunosuppressive tumor macrophages M2 types that
are more active in Hp1 carriers inducing a switch for a Th2 antinflammatory cytokine profile
characteristic of lesser Th1 type cytotoxic immune antitumor mechanisms (Van Vlierberghe
et al 2004, Guetta et al 2007, Nielsen MJ et al 2010, Vallelian F et al 2011 and Akila P et al 2012).
This switch can be also dependent of a stronger acute phase response characteristic of Hp1
carriers that can modulate immune cells activity after binding of Hp to its receptors CD22, β2
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integrin and LFA located respectively in B cells neutrophils and T cells (EL Ghmati SM et al
1996, Giannoni E et al 2003, Bottini N et al 1999 and 2005, Arredouani MS et al 2005, Lu JY et
al 2007). A third mechanism can be the interaction of environmental factors such as sex steroid
hormones and glucocorticoids that activates predominantly Th2 arm of acquired immunity in
synergy with Hp1 allele as happens in cervical cancer (Gleeson M 2006, Bicho MC et al 2009,
Akila P et al 2012).
An increased prevalence of Hp 2-2 genotype is observed in some tumours leading to the
hypothesizes of haptoglobin involvement in the mechanisms associated with the carcinogen‐
esis and tumorigenesis of the chronic inflammation (head and neck carcinomas, glioblastome,
gastric carcinoma).
The lower antioxidative capacity and inhibition of prostaglandin synthase associated to the
genotype Hp 2-2 are the best known explanatory mechanisms (Wen WN et al 2001, Saeed SA
et al 2007). Indirect effects of prostaglandins on carcinogenesis are mediated through the
stabilization of HIF1α and the resultant expression of angiogenic factors like EPO (erythro‐
poietin), VEGF (vascular endothelial growth factor), that have synergic effects with Hp2-2 (Cid
MC et al 1993, Liu XH et al 2002, Acs G et al 2003, Ye YN et al 2004, Mihailović M et al 2005,
Palayoor ST et al 2009, Park SJ 2009).
Another mechanism involved is the withholding of iron in macrophages that is necessary for
the proliferation of immune cell (Touitou Y et al 1985, Weinberg ED 1996, Cozzi A et al 2004).
The effects of smoking habits are modulated by Hp2-2, because the effects in the nicotine down
regulation of haptoglobin expression and also the effects of CO producing local hypoxia and
the immune depression (Ye YN et al 2005).
7. Perspectives
More studies are necessary to complete our understanding about the role of this important
acute phase protein, its levels variations, particularly the fucosylated isoforms and its regula‐
tion, the Hpr and its polymorphism and its immunomodulation role in cancer. Finally, future
studies may focus in the importance of haptoglobin polymorphism conducting to a pharma‐
cogenetic approach to chemoprevention.
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